

Evolving Treatment of Advanced Hepatocellular Carcinoma in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197840>

May 27, 2021 · In the phase 3 study of **first-line** combination **therapy** with the programmed cell-death 1 ligand 1 (PDL1) inhibitor **atezolizumab** and the vascular endothelial growth factor (VEGF) inhibitor **bevacizumab** versus standard-of-care sorafenib for **advanced** HCC (IMbrave150 trial, NCT03434379), **treatment** with the novel combination resulted in significantly ...

Author: Sadahisa Ogasawara, Su-Pin Choo, Jian... **Publish Year:** 2021

Immunotherapy Updates in Advanced Hepatocellular Carcinoma

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125389>

Apr 30, 2021 · First, **atezolizumab** plus **bevacizumab** is now the only **therapy** to demonstrate improved OS and PFS for the **first-line treatment** of **advanced** HCC compared to sorafenib. Importantly, the median OS of 13.4 months seen in the sorafenib arm of the IMbrave150 study is numerically greater than previous reports of front-line sorafenib use in both the SHARP ...

Cited by: 2

Author: Amisha Singh, Ryan J Beechinor, Jasmine ...

Publish Year: 2021

People also ask

When to use atezolizumab in a clinical trial?



Which is the best immunotherapy for advanced hepatocellular carcinoma?



Name of Journal: *World Journal of Hepatology*

Manuscript NO: 66856

Manuscript Type: MINIREVIEWS

Atezolizumab and bevacizumab as first line therapy in Advanced Hepatocellular Carcinoma- "Practical Considerations in routine clinical practice".

Atezolizumab and Bevacizumab in advanced HCC

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. For advanced HCC, sorafenib was considered the standard of care for more than ten years. Recently the atezolizumab and bevacizumab combination has become standard of care for these patients without contraindications to either immune checkpoint inhibitors or antiangiogenic therapy. We now review the practical aspects of the atezolizumab and bevacizumab combination, including current evidence, indications, contraindications

Match Overview

1	Crossref 128 words Peter R Galle, Richard S Finn, Shukai Qin, Masafumi Ikeda et al. "Patient-reported outcomes with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: results from the phase 3 IMbrave151 trial."	3%
2	Crossref 96 words Martine Fritsch, Bernhard Scheiner, Markus Peck-Radosi ... etic. "Immunotherapy for advanced hepatocellular carcinoma: a review of the literature."	2%
3	Internet 65 words crawled on 25-Nov-2020 clinicaltrials.gov	2%
4	Internet 59 words crawled on 22-Sep-2020 research.kndai.ac.jp	1%
5	Internet 31 words crawled on 14-Jun-2021 www.nice.org.uk	1%
6	Crossref 30 words Marion Allaire, Marika Rudler, Dominique Thabut. "Portal hypertension and hepatocellular carcinoma: Des leçons d'un cas."	1%
7	Crossref 27 words L. Cardarelli-Lelle, A. Hadjivassiliou, D. Klass, J. Chung, S. G. F. Ho, H. J. Lim, P. T. W. Kim, A. Mupondar, D. M. Liu ...	1%
8	Crossref 24 words Michael S Lee, Baek-Yeol Ryou, Chih-Hung Hsu, Kazushi Nishimura et al. "Atezolizumab with or without bevacizumab in advanced hepatocellular carcinoma: a phase 3 randomized controlled trial."	1%

国内版

国际版

Atezolizumab and bevacizumab as first line therapy in advanced h



ALL

IMAGES

VIDEOS

11,700 Results

Any time ▾

[Evolving Treatment of Advanced Hepatocellular Carcinoma ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197840>

May 27, 2021 · In the phase 3 study of **first-line combination therapy** with the programmed cell-death 1 ligand 1 (PDL1) inhibitor **atezolizumab** and the vascular endothelial growth factor (VEGF) inhibitor **bevacizumab** versus standard-of-care sorafenib for **advanced HCC** (IMbrave150 trial, NCT03434379), **treatment** with the novel combination resulted in significantly ...

Author: Sadahisa Ogasawara, Su-Pin Choo, Ji... Publish Year: 2021

[Hepatocellular Carcinoma: An Overview of the Changing ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128500>

May 13, 2021 · Particularly, the novel doublet of **atezolizumab** plus **bevacizumab** is indicated as a **first-line** option for patients (Child-Pugh A, ECOG PS 0–1) without a history of co-infection with hepatitis B and hepatitis C, autoimmune disease, or bleeding predisposition. 18 Lenvatinib is considered a **first-line treatment** for non-excisable HCCs, while ...

Author: Andreas Koulouris, Christos Tsagkaris... Publish Year: 2021

[\(PDF\) Clinical Outcomes with Multikinase Inhibitors after ...](#)

<https://www.researchgate.net/publication/350330370...>

Introduction: **Atezolizumab-bevacizumab** is the new standard of care for **first-line treatment** of **advanced hepatocellular carcinoma (HCC)**. However, the optimal sequence of **therapy** after disease ...

[Atezolizumab plus Bevacizumab in Unresectable ...](#)

<https://www.researchgate.net/publication/341368246...>

Introduction The **treatment** of **unresectable hepatocellular carcinoma (HCC)** has radically changed after the approval of the combination of **atezolizumab** plus **bevacizumab** as **first-line treatment**.

Estimated Reading Time: 11 mins

[Immune-Checkpoint Inhibitors for Advanced Hepatocellular ...](#)

<https://theoncologist.onlinelibrary.wiley.com/doi/10.1002/onco.13776>

Apr 05, 2021 · Immune-checkpoint inhibitors (ICIs) can provide high objective response rates (ORR, estimated with RECIST 1.1. criteria) when used as **first-line treatment** in **advanced hepatocellular carcinoma**, particularly pembrolizumab + lenvatinib (ORR 36%) or **atezolizumab** + **bevacizumab** ...